Kadmon has started the Phase IIa portion of a Phase Ib/IIa study of KD020 in autosomal dominant polycystic kidney disease (ADPKD), following unanimous recommendation of the study’s data safety committee.

KD020 is an orally bioavailable small molecule kinase inhibitor of Src, HER2, EGFR and VEGFR2/KDR, in ADPKD.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The Phase IIa study will assess the activity, safety and tolerability of an alternate dosing schedule of 150mg of KD020 administered three times weekly.

"With primary outcome measures of total kidney volume and glomerular filtration rate, the Phase IIa portion of the study is likely to recruit around 25 patients."

With primary outcome measures of total kidney volume and glomerular filtration rate, the Phase IIa portion of the study is likely to recruit around 25 patients.

In the Phase Ib portion of the study, KD020 was generally well-tolerated, with rash (Grade 2) as the most common > Grade 1 adverse event in the highest dose cohort (150mg daily), according to the company.

Kadmon chairman and CEO Samuel Waksal said: "We are encouraged by the initial tolerability profile of KD020, and look forward to understanding its broader potential in addressing ADPKD through the Phase IIa portion of the study."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

ADPKD, which is caused by a mutation in either the polycystin 1 or 2 (PKD1 or PKD2) genes, involves the formation of cysts in the kidney, leading to destruction of the kidney parenchyma and loss of renal function.

With no current disease modifying approved therapies, ADPKD is the most prevalent monogenic disease in the US and globally, affecting about 600,000 Americans and about 12.5 million people worldwide.